Department of Cardiology, AP-HP, Saint Antoine Hospital, UNICO Cardio-oncology program, GRC n(o) 27, 184, rue du faubourg saint Antoine, 75012 Paris, France.
Department of Cardiology, AP-HP, Pitié-Salpétrière Hospital, UNICO Cardio-oncology program, 75012 Paris, France.
Therapie. 2022 Mar-Apr;77(2):197-206. doi: 10.1016/j.therap.2021.09.008. Epub 2021 Nov 25.
Cardio-oncology is an emerging field that transformed the medical management of patients with cancer. It encompasses the prevention and treatment of cardiovascular toxicities related to cancer treatments, aiming to reduce cardiac adverse events among cancer survivors. Cardiovascular toxicities related to cancer treatments are described through data collected during phase I to phase III therapeutic trials, and post-marketing surveillance (phase IV). Pharmacovigilance analyses, based on datamining from these extensive databases, allowed to understanding and identifying new adverse drug reactions, some recently made available, such as immunotherapy or inhibitor of Bruton tyrosine kinase (IBTK).
心脏肿瘤学是一个新兴领域，改变了癌症患者的医学管理方式。它涵盖了预防和治疗与癌症治疗相关的心血管毒性，旨在减少癌症幸存者的心脏不良事件。与癌症治疗相关的心血管毒性通过 I 期至 III 期治疗试验和上市后监测（IV 期）期间收集的数据来描述。基于从这些广泛数据库中进行数据挖掘的药物警戒分析，有助于了解和识别新的药物不良反应，其中一些最近已经出现，例如免疫疗法或布鲁顿酪氨酸激酶抑制剂（IBTK）。
